At 12 months, tumor-freezing plus hormone therapy had a 97.5% response rate in 40 breast cancer patients.

IceCure Medical (ICCM) presented 12-month clinical data for its ProSense® breast cancer cryoablation system at EUSOBI, showing a 97.5% response rate in 40 patients. The company hosted workshops and scientific sessions, highlighting strong physician engagement and growing interest in the minimally invasive treatment.

Original reporting
Published Oct 13, 2026, 12:05 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Oct 13, 2026, 12:09 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefFinancial news
Primary signal
$ICCM
Bullish
high confidence
Mentioned
$ICCM
Relevance
8/10
AlphAI data visualization · based on stocktitan.net
Decision brief

The 30-second read

$ICCMBullishMed
01

Why it matters

The disclosed 97.5% response rate could drive sales growth, improve market perception, and attract further clinical adoption.

02

Market read

Strong trial results for a niche oncology device may lift ICCM's stock and influence the medical‑device sector.

03

What to watch

Reimbursement policies and competitive landscape for breast‑cancer treatments could temper upside.

Relevance 8/10Novelty 8/10Timing: today

Background

IceCure Medical (Nasdaq: ICCM) develops liquid‑nitrogen cryoablation systems. The ProSense® system is the only FDA‑cleared device for certain breast‑cancer patients.

Company-level read

Ticker impact

$ICCMBullishHigh confidence
Context

IceCure Medical disclosed 12‑month tumor‑free response rate of 97.5% in 40 breast‑cancer patients for its ProSense® cryoablation system.

Expected impact

likely upward pressure as the market prices in the strong efficacy results.

Evidence & confidence

First disclosure of robust 12‑month outcomes; no prior public data on this cohort.

Market effects

May increase interest in minimally invasive oncology devices and boost the broader medical‑device sector.

Potentially strengthens IceCure's position in U.S., European and Asian markets where the device is cleared.

Highlights growing adoption of cryoablation technology worldwide.

Counterpoint

Skeptics may question the small sample size and limited patient population before committing capital.

Key entities

  • IceCure Medical

    Developer of the ProSense® cryoablation system.

  • EUSOBI

    European breast imaging society where the data were presented.

Related articles

$ICCMMed

IceCure Successfully Completes First Cryoablation Treatment in Its ChoICE Post-Marketing Study for Breast Cancer Cryoablation

IceCure Medical (ICCM) announced the successful treatment of the first patient in its ChoICE post-marketing study for breast cancer cryoablation. The study, led by West Cancer Center in Tennessee, aims to enroll 400 patients across 30 U.S. sites. The company's ProSense® system is FDA-cleared for specific breast cancer treatments. IceCure expects the study to support broader adoption of its cryoablation technology.

$ICCMMedAI 8/10

A breast cancer study treats its first patient by freezing a tumor

IceCure Medical (ICCM) treated the first patient in its ChoICE Study at West Cancer Center, using its ProSense® cryoablation system for breast cancer. The study aims to enroll 400 patients across 30 U.S. sites, generating real-world data. ProSense® is FDA-cleared for specific breast cancer treatments. IceCure develops cryoablation therapy systems for tumor destruction.

$ICCMHighAI 8/10

IceCure Medical Wins Regulatory Approval To Market ProSense In China

IceCure Medical (ICCM) received regulatory approval from China's NMPA for its ProSense cryoablation system, expanding its global market. The device, already cleared in the U.S. and Europe, is used to treat tumors in breast, kidney, bone, and lung. The approval was supported by clinical data, and the company plans to accelerate commercialization in China. ICCM's stock is up 1.42% to $2.14.

$ICCMMed

West Cancer Center Receives IRB Approval to Commence IceCure's ChoICE Study for Breast Cancer Cryoablation

IceCure Medical (ICCM) received IRB approval from West Cancer Center for its ChoICE study on ProSense® cryoablation for low-risk breast cancer. The study, expected to enroll patients soon, aims to gather real-world data on the treatment. ProSense® is FDA-approved for women 70+ with low-risk tumors. The study will involve 30 sites and 400 patients, expanding access to cryoablation.

$ICCMMed

IceCure Medical (ICCM) Q2 2026 Earnings Call Transcript

IceCure Medical (ICCM) reported $1.8M in H1 2026 revenue, up 45% YoY. U.S. revenue grew 64% post-FDA clearance. Gross profit rose 57% to $548K, but net loss widened to $8.8M. Cash increased to $12M after $8.5M Q2 financing. Management highlighted growth in system and disposable probe sales, U.S. expansion, and the CHOICE study.